Pharmafile Logo

13th Edition – Spring MEDAFFAIRS Leaders Forum

March 5, 2020 |  

OPEN VIE (Amanda Pulfer, Strategic Director and Sergio Diaz, Patient Centred Outcomes Consultant) were delighted to speak at the Medical Affairs Leaders Forum yesterday.

- PMLiVE

We explored considerations around early evidence generation in the product development process, with a focus on the importance of collaboration with internal and external stakeholders and the importance of involving patients as peers rather than simply as study subjects.

- PMLiVE

One of the key drivers for early evidence generation is that the bench to patient pathway is on ‘fast forward’ in areas of high clinical unmet need and hence value data for payers is required months or years earlier than previously. Pharma should consider including value endpoints in Phase 2/Phase 3 studies or running a RWE evidence generation programme alongside clinical trials to ensure data is available when required.

Pink divider

OPEN VIE is a global, technology enabled, evidence and access consultancy, with a focus on patient centricity. We work with you to understand, demonstrate and communicate value to inspire change

If you would be interested to know how OPEN VIE can help with your real world evidence and market access needs, please contact:

Amanda Pulfer, Strategic Director, OPEN VIE

AmandaPulfer@openvie.com

This content was provided by OPEN Health

Company Details

 Latest Content from  OPEN Health 

Spotlight interview: 15 minutes on digital in medical communications

Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications

Generating data on long-term outcomes with gene and other advanced therapies

Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.

Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?

A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest....

Spotlight interview: 15 minutes on insights and market research in pharma

Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma

OPEN Health reflections on the World Orphan Drug Congress in Barcelona

Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...

Patient journey mapping: exploring the clinical and the emotional journey

By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...

OPEN Health announces the integration of Pharmerit International into the group

OPEN Health has today announced the integration of Pharmerit International, a global leader in health economics and outcomes research (HEOR), into its group of companies.

OPEN Health mobilised to support outcomes with gene and other advanced therapies

Harnessing the power of collaborations to bring real insights and improve outcomes

Spotlight interview: 15 minutes on PR in pharma

Vicky Bramham, Managing Director, OPEN Health takes 15 minutes to answer some key questions on PR discipline.

OPEN Health PBC recognised as No. 1 independent creative agency

We’re No.1! PMLive have named OPEN Health Patient & Brand Communications as the no.1 independent creative healthcare agency. The aim of the PMLive Top 10 lists is to highlight those...